Status:
ENROLLING_BY_INVITATION
Evaluating the Feasibility and Acceptability of Inhalation Aromatherapy for Patients Undergoing Autologous Haematopoietic Stem Cell Transplant (HSCT)
Lead Sponsor:
Singapore General Hospital
Collaborating Sponsors:
National Cancer Centre, Singapore
Conditions:
Chemotherapy-Induced Nausea and Vomiting (CINV)
Eligibility:
All Genders
21-99 years
Phase:
NA
Brief Summary
The goal of this clinical trial is to evaluate whether aromatherapy inhaler sticks can reduce nausea and vomiting in patients receiving chemotherapy as part of their stem cell transplant treatment. Th...
Eligibility Criteria
Inclusion
- At least 21 years and older
- Able to provide informed consent
- Admitted for autologous stem cell transplant receiving melphalan conditioning chemotherapy regime
- Willing to have interviews audio-recorded
Exclusion
- Currently using essential oils of any form (e.g. diffuser, topical application,
- Known sensitivity/ allergy to essential oils
- Any olfactory impairments (i.e. conditions that impair or alter sense of smell - for example, allergic rhinitis, chronic lung disease, blocked nose)
Key Trial Info
Start Date :
May 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 24 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT07209501
Start Date
May 15 2025
End Date
June 24 2026
Last Update
December 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Singapore General Hospital
Singapore, Singapore, 169608